1409937-68-3Relevant academic research and scientific papers
Aminopiperidine sulfonamide Cav2.2 channel inhibitors for the treatment of chronic pain
Shao, Pengcheng P.,Ye, Feng,Chakravarty, Prasun K.,Varughese, Deepu J.,Herrington, James B.,Dai, Ge,Bugianesi, Randal M.,Haedo, Rodolfo J.,Swensen, Andrew M.,Warren, Vivien A.,Smith, McHardy M.,Garcia, Maria L.,McManus, Owen B.,Lyons, Kathryn A.,Li, Xiaohua,Green, Mitchell,Jochnowitz, Nina,McGowan, Erin,Mistry, Shruti,Sun, Shu-Yu,Abbadie, Catherine,Kaczorowski, Gregory J.,Duffy, Joseph L.
, p. 9847 - 9855 (2013/01/16)
The voltage-gated calcium channel Cav2.2 (N-type calcium channel) is a critical regulator of synaptic transmission and has emerged as an attractive target for the treatment of chronic pain. We report here the discovery of sulfonamide-derived, state-dependent inhibitors of Ca v2.2. In particular, 19 is an inhibitor of Cav2.2 that is selective over cardiac ion channels, with a good preclinical PK and biodistribution profile. This compound exhibits dose-dependent efficacy in preclinical models of inflammatory hyperalgesia and neuropathic allodynia and is devoid of ancillary cardiovascular or CNS pharmacology at the doses tested. Importantly, 19 exhibited no efficacy in Cav2.2 gene-deleted mice. The discovery of metabolite 26 confounds further development of members of this aminopiperidine sulfonamide series. This discovery also suggests specific structural liabilities of this class of compounds that must be addressed.
